Blood cell study may unlock kidney disease secrets
NCT ID NCT05894512
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study looked at immune cells (T and B cells) in the blood of 44 people with a kidney disease called membranous nephropathy. Researchers wanted to see how these cells relate to treatment response and disease relapse. They also measured specific antibodies linked to the disease. The goal was to better understand the disease, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
44 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with biopsy-proven membranous nephropathy (study group) and IgA nephropathy (control group).
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Having a diagnosis of primary membranous nephropathy (patient group). * Having a diagnosis of primary IgA nephropathy (diseased control group). * Being healthy (healthy control group). * Agreeing to participate in the research (informed consent). Exclusion Criteria: * Refusing to participate in the research.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Membranous nephropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istanbul University
Istanbul, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody drug zuberitamab takes aim at kidney disease in phase 3 trial
- Can AI learn to spot kidney disease in biopsy images?
- Kidney disease drug may train immune cells to calm themselves
- A new tool to predict kidney failure risk in membranous nephropathy?
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?